October 18, 2016 / 2:21 PM / a year ago

J&J says stable patients likely to stay with Remicade

Oct 18 (Reuters) - Johnson & Johnson, in a conference call with anlaysts:

* Says the 70 pct of patients stable on Remicade arthritis drug unlikely to switch to a biosimilar

* Says its Darzalex drug likely to become standard of care for multiple myeloma (Reporting by Ransdell Pierson)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below